|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Breast Neoplasms | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Breast Diseases | |||||
| Neoplasms by Site | |||||
| Skin Diseases | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| 17-alpha-hydroxy-progesterone caproate | |||||
| Progesterone | |||||
| 5 | More general drug interventions related to this trial | ||||
| Estradiol Antagonists | |||||
| Estrogen Antagonists | |||||
| Estrogen Receptor Modulators | |||||
| Hormone Antagonists | |||||
| Hormones | |||||
| Hormones, Hormone Substitutes, and Hormone Antagonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Progestins | |||||
| 6 | Sponsors listed in this trial | ||||
| Tata Memorial Hospital | |||||
| Ministry of Science and Technology, India | |||||